298 related articles for article (PubMed ID: 25127862)
1. The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.
Borge M; Remes Lenicov F; Nannini PR; de los Ríos Alicandú MM; Podaza E; Ceballos A; Fernández Grecco H; Cabrejo M; Bezares RF; Morande PE; Oppezzo P; Giordano M; Gamberale R
J Immunol; 2014 Sep; 193(6):3165-74. PubMed ID: 25127862
[TBL] [Abstract][Full Text] [Related]
2. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
3. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Benkisser-Petersen M; Buchner M; Dörffel A; Dühren-von-Minden M; Claus R; Kläsener K; Leberecht K; Burger M; Dierks C; Jumaa H; Malavasi F; Reth M; Veelken H; Duyster J; Zirlik K
PLoS One; 2016; 11(12):e0169159. PubMed ID: 28036404
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
[TBL] [Abstract][Full Text] [Related]
5. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
[TBL] [Abstract][Full Text] [Related]
6. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic cells enhance sphingosine-1-phosphate receptor 1 dependent macrophage migration.
Weichand B; Weis N; Weigert A; Grossmann N; Levkau B; Brüne B
Eur J Immunol; 2013 Dec; 43(12):3306-13. PubMed ID: 23934754
[TBL] [Abstract][Full Text] [Related]
8. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis.
Sic H; Kraus H; Madl J; Flittner KA; von Münchow AL; Pieper K; Rizzi M; Kienzler AK; Ayata K; Rauer S; Kleuser B; Salzer U; Burger M; Zirlik K; Lougaris V; Plebani A; Römer W; Loeffler C; Scaramuzza S; Villa A; Noguchi E; Grimbacher B; Eibel H
J Allergy Clin Immunol; 2014 Aug; 134(2):420-8. PubMed ID: 24679343
[TBL] [Abstract][Full Text] [Related]
10. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
11. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
von Wenckstern H; Zimmermann K; Kleuser B
Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
[TBL] [Abstract][Full Text] [Related]
12. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia.
Patrussi L; Capitani N; Martini V; Pizzi M; Trimarco V; Frezzato F; Marino F; Semenzato G; Trentin L; Baldari CT
Cancer Res; 2015 Oct; 75(19):4153-63. PubMed ID: 26282174
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow.
Maeda Y; Seki N; Sato N; Sugahara K; Chiba K
Int Immunol; 2010 Jun; 22(6):515-25. PubMed ID: 20497959
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
López-Guerra M; Xargay-Torrent S; Pérez-Galán P; Saborit-Villarroya I; Rosich L; Villamor N; Aymerich M; Roué G; Campo E; Montserrat E; Colomer D
Leukemia; 2012 Jun; 26(6):1429-32. PubMed ID: 22182921
[No Abstract] [Full Text] [Related]
16. Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma.
Koresawa R; Yamazaki K; Oka D; Fujiwara H; Nishimura H; Akiyama T; Hamasaki S; Wada H; Sugihara T; Sadahira Y
Br J Haematol; 2016 Jul; 174(2):264-74. PubMed ID: 27061580
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
18. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
19. The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined.
Jin L; Liu WR; Tian MX; Fan J; Shi YH
World J Surg Oncol; 2016 Apr; 14():131. PubMed ID: 27129720
[TBL] [Abstract][Full Text] [Related]
20. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
